Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Issue 12 (4th October 2021)

• Record Type: Journal Article
• Authors: Radin, Massimo; Schreiber, Karen; Cecchi, Irene; Bortoluzzi, Alessandra; Crisafulli, Francesca; de Freitas, Cristiano M.; Bacco, Beatrice; Rubini, Elena; Foddai, Silvia G.; Padovan, Melissa; Gallo Cassarino, Silvia; Franceschini, Franco; Andrade, Danieli; Benedetto, Chiara; Govoni, Marcello; Bertero, Tiziana; Marozio, Luca; Roccatello, Dario; Andreoli, Laura; Sciascia, Savino
• Is Part Of: Arthritis care & research. Volume 73:Issue 12(2021)
• Page Start: 1804
• Page End: 1808
• Publication Date: 2021-10-04
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.24391
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : Objective: We aimed to investigate the impact of applying the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in a previously described cohort of women with undifferentiated connective tissue disease (UCTD). Methods: This study included 133 women with UCTD. At the time of inclusion into the study, none of the patients met any classification criteria for other defined systemic connective tissue disease. Results: When applying the 2019 EULAR/ACR classification criteria to the cohort, 22 patients (17%) fulfilled the classification criteria for SLE. Patients classified as having SLE had significantly higher frequencies of mucocutaneous manifestations (23% versus 5%; P = 0.007), arthritis (59% versus 17%; P < 0.001), isolated urine abnormalities (18% versus 1%; P < 0.001), and highly specific antibodies (50% versus 15%; P < 0.001) compared to the other patients with UCTD. At follow‐up, these patients were statistically significantly more likely to also meet the 1997 ACR revised SLE criteria and the Systemic Lupus International Collaborating Clinics (SLICC) criteria (18.2% versus 1.8%; P < 0.001) compared to the other UCTD patients. Patients who were diagnosed as having SLE according to the ACR 1997 update of the SLE revised criteria and the SLICC criteria during the follow‐up scored higher on outcome measures when classified as having SLE according to the new 2019 EULAR/ACR classification criteria when compared to the other patients with UCTD (mean ± SD score 8.3 ± 3.7 versus 4.5 ± 4; P < 0.05). Conclusion: When applying the 2019 EULAR/ACR criteria for SLE in a cohort of patients with UCTD, we observed that in up to 17% of cases the original classification could be challenged. New implementation will help to identify earlier patients at higher risk of developing more severe CTD manifestations.